Lessons From Implementing a Telecolposcopy Program

Slides:



Advertisements
Similar presentations
©PPRNet 2014 Designing a PPRNet PCORI Application to Improve Adherence to USPSTF Grade D Recommendations for Cancer Screening.
Advertisements

ACRIN PA 4005: Multicenter Randomized Controlled Study of a Rapid ‘Rule-out’ Strategy Using CT Coronary Angiogram Versus Traditional Care for Low-Risk.
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Introduction Women experience distress and heightened anxiety in relation to further diagnostic evaluation of pre-cancerous cell changes of the cervix,
Evolution of Neoplasia The Uterine Cervix As a Model Raj C. Dash, MD Duke University Medical Center Durham, North Carolina.
Comparison of HPV Testing and Spectroscopy Combined with Cytology for the Detection of High- grade Cervical Neoplasia C Werner, W Griffith III, R Ashfaq,D.
COLPOSCOPY RANDOM CERVICAL BIOPSIES ENDOCERVICAL CURETTAGE S.C.P.M.G.-Fontana.
Screening for Cervical Cancer
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
AN AUDIT OF PAP SMEAR, COLPOSCOPY AND HISTOLOGY RESULTS FROM IN TUNGARU CENTRAL HOSPITAL (KIRIBATI)
1 Cervical Cancer Screening in Latvia: Present, Problems and Future Ilze Viberga, MD, PhD, Ob/Gyn.
Bayesian Modelling for Clinical Decision Support: Cervical Cancer Screening1/31 University of Pittsburgh Medical Center (UPMC) Magee-Womens Hospital (MWH)
CERVICAL SCREENING WITH LUVIVA MACHINE FOR EARLY DETECTION OF CERVICAL DYSPLASIA: EXPERIENCE FROM EKITI STATE, NIGERIA Sunday O. Omoya, Abimbola M. Obimakinde.
Women’s First Health Center Drs. Sylvester, Youngren, Lo and Sansobrino What You Should Know About Cervical Cancer: Part one in a series of four updates.
Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.
SoftPAP® A Novel Collection Device for Cervical Cytology.
Current guidelines for Cervical Cancer Screening
Chapter 6 – Data Handling and EPR. Electronic Health Record Systems: Government Initiatives and Public/Private Partnerships EHR is systematic collection.
Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Sheffield Gynaecological Cancer CentreSheffield Teaching Hospitals PRIMARY HPV SCREENING A view from colposcopy John Tidy Consultant Gynaecological Oncologist.
Screening of genital cancers Evidence Based Presented by Dr\ Heba Nour.
Morphologic Pap Test Findings in HPV Negative Women Age 30 Years and Older: What Information Will Be Lost with HPV Only Primary Screening? Brooke Henninger,
Contact: PRELIMINARY RESULTS OF FIRST HPV PRIMARY SCREENING PRIVATE SECTOR IN BUENOS AIRES FEMALE POPULATION R. Jiménez del Toro,
Cancer prevention and early detection
Public Health England leads the NHS Screening Programmes
“The challenges of colposcopy in Eastern Europe and Central Asia”
Cancer prevention and early detection
Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions ELINA VIRTANEN1, ILKKA KALLIALA2,3,
NEW SCREENING PROTOCOL WITH DUAL-STAINED CYTOLOGY TRIAGE
Colposcopic Biopsy Results of HPV 16 and 18 patients in Bartın
Cost-effectiveness Analysis for Cervical Cancer Screening Using HPV DNA Tests in Chile Franco Figueira S, BPharm student1; Cachoeira CV, MD, MBA1; Silva.
Quality issues in monitoring diagnostic and treatment performance Dr
Cancer Screening Guidelines
Division of STD Prevention, CDC
Which social representations about cancer related to HPV infection and HPV vaccine from teenagers ? Charlotte Bauquier1 & Marie Préau12
Cervical Cancer in California
Patient Registries and Health Outcomes in Diabetes: A Retrospective Study Nipa Shah, MD1; Fern Webb, PhD1; Liane Hannah, BSH1; Carmen Smotherman, MS2;
Cervical Cancer Colposcopy & Treatment
Developing a Comprehensive Site Selection Process for a Cancer Network in a Resource-Limited Settings in Sub-Saharan Africa Meg Wirth AMC Operations &
The Accuracy of Diagnostic Colposcopy Using ISCCP 2011 Classification
Efficacy of random cervical biopsy and routine endocervical curettage in subjects with normal colposcopy.
Risk factors for cervical intraepithelial neoplasia recurrence after loop electrosurgical excision procedure in HIV-1-infected and non-infected women.
Effect of Acute Kidney Injury on Chronic Kidney Disease Progression and Proteinuria: Initial Results from a Pilot Study Horne K1, Scott R1, Packington.
the National Diabetes Prevention Program in the Community
INTERPRETATION OF RESULTS & CONCLUSIONS
Retest in 12mo with HPV testing
Behavioral health integration into ambulatory practice
Updates on Pap Smear Guidelines 2014
Azure-Powered Solution Ensures Great Precision and Clinical Accuracy for Health Monitoring Kit “Security and privacy are at the core of how we develop.
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Making MDTs better Steve Falk
Monitoring HPV vaccine impact in Connecticut
Behavioral health integration into ambulatory practice
Public Health England leads the NHS Screening Programmes
This layout is for example purposes only.
BIOE 301 Lecture Sixteen.
Figure 1: Guidelines for primary cytology# screening in South Africa
Cervical Screening for Dysplasia and Cancer in Patients with HIV
Toktobaeva B, Karymbaeva S Drug Information Centre Kyrgyzstan
Primary HPV test screening
SH-sheikhhasani Gyn-oncologist
Clinical Implications
Colombian College of Clinical Engineering
No. 164: Quality Assurance and Effectiveness in Hospitals:
Mahalakshmi. A, Research Scholar and Dr
The performance of OncoE6TM cervical test in detecting cervical
Isabel C. Scarinci, PhD, MPH James Kendrick, MD Edward Partridge, MD
Multiplexable paper-based platform for bio-analyte detection
SUKHBIR SINGH SETHI Head - Digital Healthcare
New Diagnostic Tools: Relevance to Programs
Presentation transcript:

Lessons From Implementing a Telecolposcopy Program Rachel Steward1, Bonnie Betts1, Kory Kahane2 Celia Gellman3,4, Cathy Sebag3, David Levitz3, Ariel Beery3 1 Department of Women’s Health, FPA Medical, Los Angeles, CA, USA; 2 Department of Medicine, University of California- Los Angeles, CA, USA; 3 MobileODT Ltd. – Tel Aviv, Israel; 4 Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel Poster # 106 POSTER EHEALTH POS5 15 December 2018 Lessons From Implementing a Telecolposcopy Program on a High Risk Population in California Introduction Results The ubiquity of digital cameras and smartphones are changing the role of visualization within cervical cancer care. Digital cervicography efforts in Zambia [1] developed a screening program based on visualization. Mobile colposcopes have also become commercially available, making colposcopy more accessible even in remote locations. MobileODT’s mobile colposcope [2] also includes secure storage of images for remote consultation, telecolposcopy and quality assurance. Yet despite all these tools now available, there has not been rigorous analyses on a US population comparing visual methods, primarily used in low resource settings, with HPV testing and cytology. In this study, we compared cervical images with traditional screening tests in a California clinic addressing a high risk population. In this retrospective study, cervical decisions based on digital images were compared with cytology and HPV testing, with cervical intraepithelial neoplasia (CIN) 2 and CIN 3 pathology as endpoints. Our objective was to determine whether capturing colposcopic impressions during primary cervical cancer screening can improve the accuracy (sensitivity and specificity) of the screening test and provide information that could be useful in patient management. The current screening paradigm of HPV testing with cytology as a triage test lacks a test with a high positive predictive value (PPV), leading to overtreatment. As a first step, we examined visualization on a colposcopy population which has a higher prevalence of disease, comparing it to HPV testing and cytology (both ASCUS and LSIL thresholds), measured against histopathology. Our hypothesis was that visualization will improve management because it yields an immediate result. A comparison of HPV testing, visual colposcopic impression, and cytology (ASCUS and LSIL thresholds) against histopathology, with a CIN 2 endpoint is shown in Tables 1-4, respectively. Using a similar analysis, the PPV and NPV with a CIN 3 endpoint are given in Table 5. A comparison of inadequacy rates for the various tests is shown in Fig. 4. Table 1: HPV testing versus histopathology, CIN 2 endpoint. Table 3: Cytology (ASCUS threshold) versus histopathology, CIN 2 endpoint. HPV + HPV - HPV Unknown Histo + 41 9 Histo - 189 17 56 Histo Unknown 10 2 3 Cyt + Cyt - Pap Unknown Histo + 49 1 Histo - 240 12 10 Histo Unknown 11 3 Sens: 1.000 PPV: 0.178 Spec: 0.083 NPV: 1.000 Sens: 1.000 PPV: 0.170 Spec: 0.048 NPV: 1.000 Table 2: Visual colposcopic impression versus histopathology, CIN 2 endpoint. Table 4: Cytology (LSIL threshold) versus histopathology, CIN 2endpoint. Vis + Vis - Vis Unknown Histo + 22 28 Histo - 26 233 3 Histo Unknown 12 Cyt + Cyt - Pap Unknown Histo + 39 10 1 Histo - 97 155 Histo Unknown 11 3 Sens: 0.440 PPV: 0.458 Spec: 0.900 NPV: 0.892 Sens: 0.796 PPV: 0.289 Spec: 0.618 NPV: 0.939 Table 5: A comparison of PPV and NPV for 4 tests, with a CIN 3 endpoint. PPV NPV HPV 0.048 1.000 Cytology / ASCUS 0.042 Cytology / LSIL 0.089 Vis colpo. impression 0.146 0.981 Figure 1: EVA System Fig 4: Comparison of inadequacy rates for the 4 tests used in the study. A rate of 2% is considered acceptable. Methods Discussion and Conclusion A retrospective study was conducted on colposcopy patients examined using MobileODT’s mobile colposcope – the Enhanced Visual Assessment (EVA) System (Fig. 1) – which was built around a smartphone platform. The EVA System is ran by an app that collects basic patient information and stores it together with colposcopy images on a HIPAA-compliant cloud-based image portal. We compared information stored on the EVA System to the recent medical history. Patient demographics and medical history are shown in Fig. 2A-C. This study was covered by the Institutional Review Board approval of the National Cancer Institute, USA (18-NCI-00695). Patient information was collected through the patients’ electronic medical records. Specifically, HPV and cytology history, other STD history, gravida, parity, and contraceptive information was recorded. In parallel, information was also retrieved from the EVA System web portal, which contains clinical decisions recorded on a job aid (Fig. 3) at the point of care (PoC). In this retrospective study, we sought to determine whether visualization of the cervix during screening can provide information that can improve patient management. We compared the colposcopic impression to HPV testing and cytology, using CIN 2 histopathology of the colposcopic biopsy as an endpoint. Our results showed that the PPV of colposcopic visualization (46%) was higher than those of both HPV testing (18%) and cytology (ASCUS threshold at 17%, LSIL threshold at 29%). Similar trends were observed when looking at high grade lesions (CIN 3). At the time of screening, NPV is more important the PPV. However, as a triage test, the higher PPV of visualization for both CIN 2 and CIN 3 suggests that it could potentially have a role to play. In our study, both HPV testing and cytology (ASCUS threshold) performed perfectly in terms of NPV and sensitivity. The performance of cytology was indeed surprising, as it was much better than values reported in the literature. Moreover, a preliminary analysis of confounding factors showed STD history correlated with advanced disease more than gravida, parity, and age (data not shown). One of the surprising results of the current study is the high inadequacy rates of the standard of care tests. The main benefit of colposcopic impression was that the provider was only unable to make a decision at the PoC in <1% of cases. This was much lower than the comparative tests. HPV testing surprisingly had an inadequacy rate of 20%, which is problematic for a primary screening test used at a US clinic. Cytology had an inadequacy rate of 4%, which is still lower than the 2% inadequacy rate expected of cytopathology services. Histopathology had an inadequacy rate of 5%. The benefit of an immediate result offered by visualization can be substantial on those patients on a non-negligible portion of the population. Contrast Fig 3: Decision Support Job Aid on the EVA System app. (A) Screenshots of the key steps. (B) Full decision tree backbone. Geometric References [1] Parham, Groesbeck P., et al. "Population-level scale-up of cervical cancer prevention services in a low-resource setting: development, implementation, and evaluation of the cervical cancer prevention program in Zambia." PLoS One 10.4 (2015): e0122169. [2] Peterson, Curtis W., et al. "Real-time monitoring and evaluation of a visual-based cervical cancer screening program using a decision support job aid." Diagnostics 6.2 (2016): 20. Gamma Funding source: This study was funded by MobileODT Disclaimer: The presentation of this material does not imply any endorsement or recommendation by WHO. WHO disclaims any and all liability and responsibility whatsoever for any injury, death, loss, damage, use of personal data, or other prejudice of any kind whatsoever that may arise as a result of, or in connection with the procurement, distribution and/or use of any technology presented in the 4th WHO Global Forum on Medical Devices.